IHS Chemical Week

Regions :: North America :: U.S.

Roche to buy US biotech firm InterMune for $8.3 billion

8:38 AM MDT | August 25, 2014 | Natasha Alperowicz

Roche (Basel) said today that it has agreed to acquire InterMune (Brisbane, CA), a biotech company focused on R&D and commercializing therapies in pulmonology and orphan fibrotic diseases, for $8.3 billion. The offer represents a premium of 38% to InterMune’s closing price on 22 August and a premium of 63% to InterMune’s unaffected closing price on 12 August. Both companies' boards have approved the agreement. The transaction is expected to close this year.   Roche, under the terms of the agreement, will commence a tender offer by 29 August...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa